Core Viewpoint - The company announced a stock suspension starting from August 18, 2025, due to plans for issuing shares to acquire assets and raise supporting funds [1] Group 1: Stock Performance - Over the 20 trading days prior to the announcement (from July 21 to August 15, 2025), the company's stock price increased by 48.31% [1] - After excluding the impact of the broader market and industry peers, the company's stock price showed a net increase of over 20% [1] Group 2: Regulatory Risks - The company has indicated potential risks, as the China Securities Regulatory Commission may investigate the stock price fluctuations [1] - If insider trading is suspected, the transaction may be suspended, terminated, or canceled [1]

Group 1 - The company plans to issue shares to acquire 99.42% equity of Shandong Hongjitang Pharmaceutical Group Co., Ltd. from 38 counterparties, including Linuo Investment Holding Group Co., Ltd. and Linuo Group Co., Ltd. [1] - The company intends to raise supporting funds by issuing shares to no more than 35 qualified specific objects as part of the transaction [1] - The announcement includes a revised draft of the "Report on Issuing Shares to Purchase Assets and Raising Supporting Funds and Related Transactions" [1] Group 2 - The revised report updates the stock issuance price and quantity for the asset purchase, as well as the raised supporting funds [2] - The decision-making process and approval status of the transaction have been updated in the report [2] - The financial status and profitability analysis of the target company have been improved and updated in the management discussion and analysis section [2]